Darolutamide Plus ADT Cuts Prostate Cancer Progression Risk by 71% in US Trial
A US phase II trial confirms darolutamide combined with ADT dramatically improves survival in metastatic hormone-sensitive prostate cancer.
Summary
A US clinical trial called ARASEC found that combining the drug darolutamide with androgen deprivation therapy (ADT) significantly outperformed ADT alone in men with metastatic hormone-sensitive prostate cancer. Men on the combination had a 71% lower risk of disease progression and a 50% lower risk of death compared to those on ADT alone. Two-year survival rates were 89% versus 80%. Notably, this doublet approach — without chemotherapy — may offer a more tolerable option for older or frailer patients who cannot handle standard triplet therapy including docetaxel. The study used an innovative design matching patients to a historical control group, potentially accelerating future cancer trial efficiency.
Detailed Summary
Prostate cancer treatment is advancing rapidly, and a new US trial adds important evidence for a chemotherapy-free intensification strategy that could benefit a broad population of men with advanced disease.
The ARASEC phase II trial evaluated darolutamide — an androgen receptor inhibitor — combined with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). Using propensity score matching against a historical control arm from the CHAARTED trial, researchers found the combination reduced the risk of disease progression by 71% compared to ADT alone. Median progression-free survival was not yet reached in the darolutamide group versus 14.3 months in the ADT-only group.
Overall survival was also significantly improved. The darolutamide group achieved a hazard ratio of 0.50 for death, with 2-year survival rates of 89% versus 80%. Remarkably, this survival advantage persisted even though more patients in the ADT-alone arm received subsequent life-prolonging therapies after progression.
PSA response rates — a key biomarker for treatment effectiveness — were more than doubled in the darolutamide group. At 68% versus 33% achieving PSA below 0.2 ng/mL, the biological signal is strong and consistent with global findings from the ARANOTE phase III trial that led to FDA approval of darolutamide plus ADT.
For clinicians and patients, the most practical insight is that darolutamide plus ADT offers an effective, chemotherapy-free option particularly suited to older or frailer men who are poor candidates for the more aggressive triplet regimen including docetaxel. Caveats include the non-randomized external control design, which introduces potential bias despite statistical matching. The historical control cohort may not perfectly reflect current standard-of-care context, and longer follow-up data are needed to fully characterize survival outcomes.
Key Findings
- Darolutamide plus ADT reduced prostate cancer progression risk by 71% versus ADT alone in mHSPC patients.
- 2-year overall survival improved to 89% with darolutamide combination versus 80% with ADT alone.
- PSA response rates more than doubled: 68% vs 33% achieved PSA below 0.2 ng/mL with darolutamide.
- Chemotherapy-free doublet may be a strong option for older or frailer patients ineligible for docetaxel triplet therapy.
- Novel propensity score matching with external phase III control may accelerate future cancer trial designs.
Methodology
This is a meeting coverage news report from MedPage Today summarizing findings from the ARASEC phase II trial presented at the American Urological Association 2026 annual meeting. The study used a prospectively enrolled treatment arm matched via propensity scoring to a historical external control from the phase III CHAARTED trial, a design that introduces selection bias limitations. MedPage Today is a credible, peer-reviewed medical news source targeting clinicians.
Study Limitations
The external control arm design, though statistically adjusted, cannot fully replicate a randomized controlled trial and may introduce confounding. The historical CHAARTED control cohort predates current treatment norms, potentially overstating the benefit of the combination. Full peer-reviewed publication and longer-term follow-up data are needed before definitive clinical conclusions are drawn.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.